Skip to content

Matthew Sale

    • 3PublicationsNumber of items in Matthew's My Publications folder on Mendeley.

    Research interests

    Recent publications

    • The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.

      • Sale M
      • Cook S
      N/AReaders
      N/ACitations
    • Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.

      • Little A
      • Balmanno K
      • Sale M
      • et al.
      N/AReaders
      N/ACitations